{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.3","upperLimit":"86.6","value":"82.7"},{"groupId":"OG001","lowerLimit":"77.8","upperLimit":"89.2","value":"84.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"341"},{"groupId":"OG001","value":"176"}],"units":"Participants"}],"title":"Anti-HPV 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81.0","upperLimit":"88.9","value":"85.2"},{"groupId":"OG001","lowerLimit":"81.0","upperLimit":"91.7","value":"87.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"332"},{"groupId":"OG001","value":"169"}],"units":"Participants"}],"title":"Anti-HPV 11"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"95.0","upperLimit":"98.8","value":"97.3"},{"groupId":"OG001","lowerLimit":"95.0","upperLimit":"99.6","value":"98.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"338"},{"groupId":"OG001","value":"173"}],"units":"Participants"}],"title":"Anti-HPV 16"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75.5","upperLimit":"84.2","value":"80.1"},{"groupId":"OG001","lowerLimit":"77.4","upperLimit":"88.8","value":"83.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"347"},{"groupId":"OG001","value":"178"}],"units":"Participants"}],"title":"Anti-HPV 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.4","upperLimit":"93.0","value":"90.1"},{"groupId":"OG001","lowerLimit":"87.8","upperLimit":"96.0","value":"92.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"343"},{"groupId":"OG001","value":"177"}],"units":"Participants"}],"title":"Anti-HPV 31"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81.0","upperLimit":"88.8","value":"85.2"},{"groupId":"OG001","lowerLimit":"83.8","upperLimit":"93.4","value":"89.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"344"},{"groupId":"OG001","value":"178"}],"units":"Participants"}],"title":"Anti-HPV 33"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.2","upperLimit":"85.9","value":"81.8"},{"groupId":"OG001","lowerLimit":"87.2","upperLimit":"95.8","value":"92.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"325"},{"groupId":"OG001","value":"169"}],"units":"Participants"}],"title":"Anti-HPV 45"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"84.4","upperLimit":"91.4","value":"88.2"},{"groupId":"OG001","lowerLimit":"83.7","upperLimit":"93.4","value":"89.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"176"}],"units":"Participants"}],"title":"Anti-HPV 52"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"94.0","upperLimit":"98.2","value":"96.5"},{"groupId":"OG001","lowerLimit":"93.5","upperLimit":"99.1","value":"97.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"175"}],"units":"Participants"}],"title":"Anti-HPV 58"}],"denoms":[{"counts":[{"groupId":"OG000","value":"971"},{"groupId":"OG001","value":"301"}],"units":"Participants"}],"description":"Serum antibody titers for HPV VLPs Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was determined and reported in milli Merck Units/mL. The percentage of participants seropositive to each HPV type was reported. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.","dispersionType":"95% Confidence Interval","groups":[{"description":"In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2).","id":"OG000","title":"Extension Study: 9- to 15-Year-Old Females"},{"description":"In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2)","id":"OG001","title":"Extension Study: 9- to 15-Year-Old Males"}],"paramType":"NUMBER","populationDescription":"All participants who met the following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range.","reportingStatus":"POSTED","timeFrame":"Up to ~Month 126","title":"Extension Study: Percentage of Participants Who Are Seropositive to Each of the HPV Types Contained in the Vaccine","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}